[Form 4] Turn Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

Turn Therapeutics Inc. director Arthur F. Golden received a grant of stock options for 89,584 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments beginning on June 30, 2026, contingent on continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this award, Golden holds 89,584 option-based rights directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GOLDEN ARTHUR F

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	89,584	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 89,584 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 89,584 options Exercise price: $5.75 per share Expiration date: June 4, 2036 +2 more

5 metrics

Options granted 89,584 options Stock option grant to director Arthur F. Golden

Exercise price $5.75 per share Strike price of newly granted options

Expiration date June 4, 2036 Option term end for this grant

Total options after grant 89,584 options Holdings following reported transaction

Vesting schedule 12 equal monthly installments Vesting starts June 30, 2026

Key Terms

Stock option (right to buy), exercise price, vest in twelve (12) equal monthly installments, Omnibus Incentive Plan

4 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "5.7500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in twelve (12) equal monthly installments financial

"The option will vest in twelve (12) equal monthly installments"

Omnibus Incentive Plan financial

"Issuer's 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDEN ARTHUR F

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.75	06/04/2026		A		89,584		(1)	06/04/2036	Common Stock	89,584	$0	89,584	D

Explanation of Responses:

1. The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

	/s/ Zuraiz Chaudhary, attorney-in-fact for Arthur Golden	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Turn Therapeutics (TTRX) report for Arthur F. Golden?

Turn Therapeutics reported that director Arthur F. Golden received a grant of stock options for 89,584 shares. These options give him the right to buy common stock at a fixed price if vesting and other conditions are met.

What is the exercise price of Arthur F. Golden’s new Turn Therapeutics (TTRX) stock options?

The new stock options granted to Arthur F. Golden have an exercise price of $5.75 per share. This is the price he must pay to convert each option into one share of Turn Therapeutics common stock after vesting.

How do Arthur F. Golden’s Turn Therapeutics (TTRX) options vest?

Arthur F. Golden’s options vest in twelve equal monthly installments starting on June 30, 2026. Vesting is subject to his continued employment and the specific terms and conditions of the applicable option award and the 2025 Omnibus Incentive Plan.

When do Arthur F. Golden’s Turn Therapeutics (TTRX) stock options expire?

The granted stock options expire on June 4, 2036. After this expiration date, any unexercised options become worthless, so Golden must exercise vested options before this deadline if he chooses to acquire common shares.

Did Arthur F. Golden buy or sell any Turn Therapeutics (TTRX) shares in this Form 4?

The Form 4 shows a grant of stock options to Arthur F. Golden, not an open-market purchase or sale of shares. It reflects a compensation-related award, with no reported buying or selling of common stock in the market.

How many Turn Therapeutics (TTRX) options does Arthur F. Golden hold after this grant?

Following this grant, Arthur F. Golden holds 89,584 stock options directly. Each option represents the right to purchase one share of Turn Therapeutics common stock at the specified exercise price, subject to vesting and plan conditions.